Atomo Diagnostics featured in Stockhead article on point-of-care medical testing

Atomo Diagnostics has been featured in a recent Stockhead article, “ASX companies behind faster point-of-care medical testing”, published on 28 October 2026.

The article examines the growing global point-of-care testing market and highlights a number of Australian companies operating in the sector, including Atomo Diagnostics.

Within the feature, Atomo is recognised for its work in rapid diagnostic testing, including its HIV self-test portfolio and OEM technology capabilities. The article also notes Atomo’s interest in supporting access to HIV self-testing in Fiji following the country’s declaration of a public health emergency.

The coverage includes commentary from Atomo Diagnostics CEO and Managing Director, Dr Cheri Walker, who outlines the company’s strategic focus across both self-testing and professional healthcare applications.

The article also references Atomo’s broader product pipeline, including its active syphilis test and liver function and monitoring test, as well as the company’s role as an original equipment manufacturer supporting other diagnostic platforms.

This media coverage reflects growing interest in decentralised diagnostics and the important role accessible, well-designed point-of-care solutions can play in improving testing access and usability across a range of healthcare settings.

Read the original article on Stockhead

Source: Stockhead, Nadine McGrath, 28 October 2026

To learn more about Atomo Diagnostics and our portfolio of rapid diagnostic technologies, visit www.atomodiagnostics.com.